Medical Segment Sets to Grow Further Moving into 4Q23, the group is confident that the medical segment contribution will increase by 15-20% QoQ driven by higher sales to Edward (40% of 3Q23 revenue) and recovery in orders from Ambu (29% of 3Q23 revenue). We note that Supercomnet has been chosen by Edwards Lifesciences (market cap of above USD50bn) as the best quality supplier (more than 700 suppliers) and achieved gold status in 2023. Edward will be using more digital smart cable (from analog cable) for its products such as its inbuilt PCB Board somewhere in the middle of 2024. For Ambu, the growth will come from endoscopes, gastroscopes and colonoscope (US FDA approved in Sep-23).
Price is rather high (PE 34x) while future upside is not that great.. Mermaid orders would be halted in April this year. Though it’s mentioned to be resumed by Sept when internal dispute is settled, there is uncertainty whether the dispute can be settled by then..
better wait for it the price to be cheaper first then only enter..
Be cautious of this company. Between August 2020 and March 2024, they have continually added 170,117,400 shares through additional listings, which dilutes shareholder benefits. This trend of adding approximately 3,956,218 shares per month continues.
The management of this listed company is not sincere in fostering business growth; instead, they manipulate share units for their own benefit.
c328 , the Company issued FREE warrant of 1:3 to all existing shareholders on 2019, then they are eligible to convert warrant at RM0.65 per share (which the price are similar at the mother share price at 2019). So the convertion is a REWARD to shareholders who hold long term.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Xcalibre
504 posts
Posted by Xcalibre > 2024-01-17 14:40 | Report Abuse
Medical Segment Sets to Grow Further
Moving into 4Q23, the group is confident that the medical segment contribution will increase by 15-20% QoQ driven by higher sales to Edward (40% of 3Q23 revenue) and recovery in orders from Ambu (29% of 3Q23 revenue). We note that Supercomnet has been chosen by Edwards Lifesciences (market cap of above USD50bn) as the best quality supplier (more than 700 suppliers) and achieved gold status in 2023. Edward will be using more digital smart cable (from analog cable) for its products such as its inbuilt PCB Board somewhere in the middle of 2024. For Ambu, the growth will come from endoscopes, gastroscopes and colonoscope (US FDA approved in Sep-23).